AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12032162 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (CO) diet
Number of subjects: 26
Study 12032162 — intervention group
Group type: COMPARATOR
Intervention: Olive/sunflower oil (O/SO) diet
Number of subjects: 26
Study 9952060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 g/kg ethanol
Number of subjects: 11
Study 9952060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60 g/kg ethanol
Number of subjects: 11
Study 9952060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7799016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 399
Study 7799016 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 399
Study 2316795 — intervention group
Group type: EXPERIMENTAL
Intervention: Government Pharmaceutical Organization of Thailand antivenom (mostly F(ab)2 fragments)
Number of subjects: 26
Study 2316795 — intervention group
Group type: EXPERIMENTAL
Intervention: Twyford antivenom of caprine origin
Number of subjects: 26
Study 2316795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai Red Cross antivenom
Number of subjects: 26
Study 2316795 — intervention group
Group type: EXPERIMENTAL
Intervention: All antivenoms
Number of subjects: 26
Study 396687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled clemastine
Number of subjects: 11
Study 396687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30407031 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging gait and balance training (including single and dual-task conditions)
Number of subjects: 100
Study 30407031 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 100
Study 27539604 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450
Study 27539604 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450
Study 27539604 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study 25711322 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA <50 copies/mL
Number of subjects: 4676
Study 25711322 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA between 51 and 400 copies/mL
Number of subjects: 4676
Study 25711322 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with low HIV RNA
Number of subjects: 4676
Study 25711322 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV antibody positivity
Number of subjects: 4676
Study 25711322 — intervention group
Group type: EXPERIMENTAL
Intervention: Race and HBV surface antigen positivity
Number of subjects: 4676
Study 23372725 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 30
Study 23372725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-practice/self-reflection workbook
Number of subjects: 16
Study 19726820 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge 2 hours following successful PCI with adjunctive bivalirudin therapy and a femoral arterial closure device
Number of subjects: 39
Study 19726820 — intervention group
Group type: COMPARATOR
Intervention: Routine care with an overnight hospital stay
Number of subjects: 39
Study 19726820 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 39
Study 19726820 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 39
Study 17349088 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched foods (EPA + DHA intake of 1 g/d)
Number of subjects: 86
Study 17349088 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 86
Study 15078017 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made soft contact lenses (SCLs)
Number of subjects: 23
Study 15078017 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard soft contact lenses (SCLs)
Number of subjects: 23
Study 15078017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberration-free soft contact lenses (SCLs)
Number of subjects: 23
Study 15078017 — intervention group
Group type: COMPARATOR
Intervention: Best-correcting spectacle lens
Number of subjects: 23
Study 11729012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 96
Study 11729012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11729012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 96
Study 9397098 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of misoprostol at 6‐hour intervals (n = 27)
Number of subjects: 81
Study 9397098 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol at 12‐hour intervals (n = 26)
Number of subjects: 81
Study 9397098 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg of gemeprost at 3‐hour intervals (n = 28)
Number of subjects: 81
Study 8359080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 126
Study 8359080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 3307842 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (45 Gy)
Number of subjects: 519
Study 3307842 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation (45 Gy)
Number of subjects: 519
Study 3307842 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 519
Study 30215301 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 45
Study 30215301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 31215685 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Bayesian adaptive (OBA) design
Number of subjects: 0
Study 31215685 — intervention group
Group type: COMPARATOR
Intervention: Equal randomization (ER) design
Number of subjects: 0
Study 28077223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice
Number of subjects: 69
Study 28077223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice and tandem skydive
Number of subjects: 69
Study 28077223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 25686344 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 62
Study 25686344 — intervention group
Group type: COMPARATOR
Intervention: Restraint
Number of subjects: 62
Study 24001698 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8863
Study 24001698 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8863
Study 21993867 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 39
Study 19593713 — intervention group
Group type: EXPERIMENTAL
Intervention: Forewarning about congestion
Number of subjects: 49
Study 19593713 — intervention group
Group type: COMPARATOR
Intervention: No warning about congestion
Number of subjects: 49
Study 16846498 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil (RPO) added to school meals (15 ml, 3 times a week)
Number of subjects: 239
Study 16846498 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A capsule (60 mg) given at the end of the school year
Number of subjects: 239
Study 16846498 — intervention group
Group type: COMPARATOR
Intervention: Red palm oil (RPO) through the school year
Number of subjects: 239
Study 14656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micro g, lockout six‐minute
Number of subjects: 60
Study 14656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micro g, lockout three‐minute
Number of subjects: 60
Study 14656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micro g, lockout three‐minute
Number of subjects: 60
Study 14656784 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 60
Study 10857368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser light exposure
Number of subjects: 83
Study 10857368 — intervention group
Group type: COMPARATOR
Intervention: Broadband lamp (BL) light exposure
Number of subjects: 83
Study 9182132 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear granulocytes count in blood
Number of subjects: 92
Study 9182132 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococci showing antagonistic activity
Number of subjects: 92
Study 1399944 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 59500 (1.4, 2.8, 4.6, 7.0, 9.8, 12.6, 16.8, 22.4, 29.4 mg/kg)
Number of subjects: 26
Study 1399944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6235453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B), 40 micrograms each, administered in three doses.
Number of subjects: 1311
Study 6235453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 1311
Study 6235453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B).
Number of subjects: 1311
Study 31049735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary exposure biomarker discovery and validation strategy based on a food intervention study
Number of subjects: 51
Study 31049735 — intervention group
Group type: EXPERIMENTAL
Intervention: Different food formulations and processing methods involving meat, wholegrain, fruits and vegetables
Number of subjects: 51
Study 31049735 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples with robust dietary biomarkers
Number of subjects: 51
Study 29767688 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Number of subjects: 0
Study 29767688 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg
Number of subjects: 0
Study 29767688 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 26170158 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG) with D2 lymph node dissection
Number of subjects: 180
Study 26170158 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 180
Study 23951281 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-isometric relaxation (PIR)
Number of subjects: 120
Study 23951281 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch combined with stabilizing exercises (SS)
Number of subjects: 120
Study 23951281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing exercises (SE)
Number of subjects: 120
Study 20385664 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral stimuli
Number of subjects: 159
Study 20385664 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pictures
Number of subjects: 159
Study 19410073 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine (Lido group)
Number of subjects: 30
Study 19410073 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Prilocaine with 1:200000 felypressin (Prilo group)
Number of subjects: 30
Study 19410073 — intervention group
Group type: COMPARATOR
Intervention: 4% Prilocaine without vasoconstrictor (Prilo‐no‐VC group)
Number of subjects: 30
Study 17298657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid smoking (RS)
Number of subjects: 100
Study 17298657 — intervention group
Group type: COMPARATOR
Intervention: Control (health promotion video)
Number of subjects: 100
Study 19780244 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with modern two-drug platinum-based combinations
Number of subjects: 0
Study 19780244 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy with alkylating agent-based therapies
Number of subjects: 0
Study 19780244 — intervention group
Group type: COMPARATOR
Intervention: Chest radiotherapy
Number of subjects: 0
Study 19780244 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 0
Study 11316508 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic belladonna 30CH
Number of subjects: 87
Study 11316508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 11316508 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 87
Study 8195454 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (nonsteroidal androgen receptor blocking agent)
Number of subjects: 3
Study 8195454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccine (RIT 4237), 3 doses administered concurrently with oral or killed polio vaccine.
Number of subjects: 276
Study 2884455 — intervention group
Group type: COMPARATOR
Intervention: Placebo/oral polio group (unvaccinated control).
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus/oral polio group.
Number of subjects: 276
Study 2884455 — intervention group
Group type: COMPARATOR
Intervention: Placebo/oral polio group.
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus/killed polio group.
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccine efficacy of RIT 4237.
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237.
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of oral polio vaccine with rotavirus vaccine.
Number of subjects: 276
Study 2884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polio and rotavirus vaccines.
Number of subjects: 276
Study 28905683 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified walk-in system
Number of subjects: 1286
Study 28905683 — intervention group
Group type: COMPARATOR
Intervention: Scheduled appointment
Number of subjects: 1286
Study 28800001 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardiometry (SVEC)
Number of subjects: 30
Study 28800001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (SVUS)
Number of subjects: 30
Study 26344094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 148
Study 26344094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 24125672 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mAs (conventional dose)
Number of subjects: 100
Study 24125672 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mAs
Number of subjects: 100
Study 24125672 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mAs
Number of subjects: 100
Study 24125672 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mAs
Number of subjects: 100
Study 24125672 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mAs
Number of subjects: 100
Study 21309444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (reducing 21‐30 Hz activity and increasing 10 Hz activity, 5 sessions for each affected site)
Number of subjects: 71
Study 21309444 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (control group)
Number of subjects: 71
Study 18342111 — intervention group
Group type: EXPERIMENTAL
Intervention: Avène thermal spring water anti burning gel (ATSW gel)
Number of subjects: 69
Study 18342111 — intervention group
Group type: COMPARATOR
Intervention: Trolamine cream (Control)
Number of subjects: 69
Study 16797393 — intervention group
Group type: EXPERIMENTAL
Intervention: iPTH/80
Number of subjects: 43
Study 16797393 — intervention group
Group type: COMPARATOR
Intervention: iPTH/120
Number of subjects: 43
Study 12890465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive retention tape Mefix
Number of subjects: 50
Study 12890465 — intervention group
Group type: COMPARATOR
Intervention: Alginate Kaltostat
Number of subjects: 50
Study 10966908 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+; 80.4 mg/d)
Number of subjects: 69
Study 10966908 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein (SPI-)
Number of subjects: 69
Study 10966908 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (control)
Number of subjects: 69
Study 9120512 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study
Number of subjects: 0
Study 9120512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 9120512 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 0
Study 9120512 — intervention group
Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 0
Study 8342427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Number of subjects: 56
Study 8342427 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 56
Study 3553280 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐blind placebo‐controlled food challenges
Number of subjects: 120
Study 3553280 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional diet sheets based on identification of 'key words' on food labels
Number of subjects: 120
Study 29610960 — intervention group
Group type: EXPERIMENTAL
Intervention: CI522
Number of subjects: 21
Study 29610960 — intervention group
Group type: EXPERIMENTAL
Intervention: CI512
Number of subjects: 21
Study 29610960 — intervention group
Group type: EXPERIMENTAL
Intervention: CI532
Number of subjects: 21
Study 27355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cook-stove intervention
Number of subjects: 664
Study 27355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic data capture using eCRFs on mobile technology
Number of subjects: 664
Study 25033582 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP reduction measured with Dynamic Contour tonometer (DCT)
Number of subjects: 60
Study 25033582 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP reduction measured with Goldmann Applanation tonometer (GAT)
Number of subjects: 60
Study 25033582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude (OPA) measured using DCT
Number of subjects: 60
Study 23370288 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28
Study 23370288 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 21114406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lukewarm saline and yoga postures (LWS/yoga)
Number of subjects: 54
Study 21114406 — intervention group
Group type: COMPARATOR
Intervention: NuLytely(®) (PEG‐3350, sodium chloride, sodium bicarbonate, and potassium chloride solution)
Number of subjects: 54
Study 17689667 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered Edinburgh Depression Scale (EDS)
Number of subjects: 407
Study 15731595 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 1580
Study 15731595 — intervention group
Group type: COMPARATOR
Intervention: Non-BIS control
Number of subjects: 1580
Study 12515739 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 0 mg
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin
Number of subjects: 44
Study 12515739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 44
Study 10773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly group psychotherapy for 4 months
Number of subjects: 20
Study 10773774 — intervention group
Group type: COMPARATOR
Intervention: Two educational sessions over a period of 1 month
Number of subjects: 20
Study 10773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 20
Study 8862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat enteral formula (41% fat calories)
Number of subjects: 36
Study 8862532 — intervention group
Group type: COMPARATOR
Intervention: High fat enteral formula (55% fat calories)
Number of subjects: 36
Study 8482178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg per os three times a day before meals)
Number of subjects: 38
Study 8482178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8482178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 38
Study 4028283 — intervention group
Group type: EXPERIMENTAL
Intervention: cephemic cofosfolactamine
Number of subjects: 127
Study 4028283 — intervention group
Group type: COMPARATOR
Intervention: cephalexin
Number of subjects: 127
Study 4028283 — intervention group
Group type: COMPARATOR
Intervention: fosfomycin
Number of subjects: 127
Study 31653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuro (ultrasound device)
Number of subjects: 130
Study 31653795 — intervention group
Group type: COMPARATOR
Intervention: Control (palpation-guided spinal anesthesia)
Number of subjects: 130
Study 31653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuro
Number of subjects: 130
Study 31653795 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 29803904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter)
Number of subjects: 0
Study 29803904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (after switching from other treatments)
Number of subjects: 0
Study 29803904 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or etanercept)
Number of subjects: 0
Study 25726428 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program + 10 g/day BCAA supplementation
Number of subjects: 0
Study 25726428 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise program
Number of subjects: 0
Study 25726428 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (both groups)
Number of subjects: 0
Study 25369174 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extract, 1g KRG extract/pouch, twice a day
Number of subjects: 70
Study 25369174 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extract
Number of subjects: 70